RCT | Short vs. extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia.

Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial – The Lancet Haematology (link to abstract – $ for full-text)

Commentary: Short-Course or Extended Antibiotics in Febrile Neutropenia? – Medscape (free registration required)

Commentary on Twitter

NEW online—Short-term is not inferior to extended carbapenem in patients with haematological malignancy and neutropenic fever of unknown origin, however, higher serious adverse events and mortality were noted in the short treatment group: the SHORT trial https://t.co/FOp1M3D6cL pic.twitter.com/6z5e8MSEgQ

— The Lancet Haematology (@TheLancetHaem) June 10, 2022